Transthera Biosciences Co. Ltd. has described NLRP3 inflammasome inhibitors reported to be useful for the treatment of autoimmune disease, inflammatory disorders and immunological disorders.

Astellas Pharma Inc. and Kotobuki Pharmaceutical Co. Ltd. have disclosed NLRP3 inflammasome inhibitors reported to be useful for the treatment of neurodegeneration and inflammatory disorders.

Merck Sharp & Dohme LLC has disclosed phthalazine derivatives acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of atherosclerosis, nonalcoholic steatohepatitis (NASH; metabolic dysfunction-associated steatohepatitis [MASH]), neuroinflammation, inflammatory skin disease, inflammatory joint disease, autoimmune disease, Alzheimer’s disease and Parkinson’s disease, among others.

Bioage Labs Inc. has synthesized NLRP3 inflammasome inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease and traumatic brain injury.

Exscientia plc has described NLRP3 inflammasome inhibitors reported to be useful for the treatment of atherosclerosis, autoimmune disease, cancer, gout, inflammatory and neurological disorders, psoriasis and sickle cell disease.

Japan Tobacco Inc. has disclosed pyrazolopyrimidine compounds acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of traumatic brain injury, inflammatory bowel disease and more.

Hangzhou Highlightll Pharmaceutical Co. Ltd. has identified NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, inflammation, liver and metabolic disease, neuroinflammation, immunological, cardiovascular and renal disorders.

Takeda Pharmaceutical Co. Ltd. has disclosed new heterocyclic compounds acting as NLRP3 inflammasome inhibitors.

AC Immune SA has identified pyrrolotriazine and imidazotriazine derivatives acting as NLRP3 inflammasome inhibitors.